First Trust NASDAQ 100 Technology Index Fund vs Twist Bioscience Corp — how do they compare? First Trust NASDAQ 100 Technology Index Fund trades at $330.53 (market cap $4.10B), while Twist Bioscience Corp trades at $161.09 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 2.5× First Trust NASDAQ 100 Technology Index Fund's market cap, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ 100 Technology Index Fund for 40 Days and Twist Bioscience Corp for 27 Days on average.
| QTEC | TWST | |
|---|---|---|
Market Cap | $4.10B | $10.08B |
Volume | 264,303 | 4,229,037 |
Sector | Broad Market / Factor | Health |
52-Week High | $340.28 | $205.00 |
52-Week Low | $207.03 | $25.45 |
Typical Hold Time | 40 Days | 27 Days |
Enterprise Value | — | $10.01B |
Signals from Pluang's Aura AI — not financial advice
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $335.82, down 1.31% on the day. Technical indicators show a bullish trend from moving averages but caution from overbought RSI levels. The ETF provides equal-weighted exposure to the technology sector, with recent analysis highlighting its broader sector definition and liquidity advantages.
The outlook for QTEC is supported by bullish technical trends and its role in tech exposure, though overbought conditions and sector volatility present risks. Investment opportunity lies in diversified tech access, but investors face market sensitivity and valuation pressures inherent to technology stocks.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →